Cerebro Pharma was established in 2020 as an Osaka-based bio-venture with the mission to create a society free of dementia. We focus on research and development of healthcare products and pharmaceuticals specializing in the prevention and improvement of dementia and neurodegenerative diseases, and actively promote collaborative projects with major domestic pharmaceutical companies and academic institutions.
[画像1: https://prtimes.jp/i/142474/11/resize/d142474-11-716ab566e146c84669a2-8.jpg ] 写真はイメージ。セレブロファーマ株式会社（本社：大阪府大阪市中央区南久宝寺町4丁目5番6号 VELTEX本町ビル3階、代表...
脳と腸の関係に着目した研究知見を背景に、植物由来素材を活用した食品の研究、開発、販売を手掛けるセレブロファーマ株式会社（本社：大阪市中央区、代表取締役：富山 貴美・松田 和則、以下「セレブロファーマ...
[画像1: https://prtimes.jp/i/142474/9/resize/d142474-9-051c687938c74b82c938-0.png ] セレブロファーマ株式会社セレブロファーマ株式会社（以下「当社」）は、2026年4月より販売しているサプリメントブランド...
大阪公立大学発ベンチャー セレブロファーマ株式会社（本社：大阪市中央区、代表取締役：富山貴美）は、帝人株式会社（本社：大阪市北区、代表取締役：内川哲茂）と共同で、漢方薬の素材である「酸棗仁」に認知症...
Utilizing the unique genome editing technology CRISPR-Cas3, C4U develops industrial applications to combat diseases that currently have no effective treatments.
A drug discovery venture tackling next-generation cancer treatment using marine-derived compounds that improve tumor hypoxia while minimizing side effects. Already commercialized as veterinary medicine, it supports the lives of both humans and pets.
Neocure prevents 30,000 children from going blind each year due to ROP using AI technology. ROP can be treated, but it is often hard to find in time. Our AI analyzes the risk for each baby, helping to prevent missed diagnoses in hospitals where there aren't enough eye specialists. By helping doctors focus on the most urgent cases, we can stop blindness caused by ROP.
Aortic stenosis is a life-threatening condition in which the aortic valve becomes severely narrowed. With an aging population, the number of patients is expected to increase dramatically worldwide in the coming years. Although valve replacement has become widely adopted, many patients are either too frail to tolerate the procedure or lack access to specialized treatment centers. As a result, a significant treatment gap still remains. DIVE, the device we are developing, synchronizes balloon expansion with the heartbeat to gently open the narrowed aortic valve. Its key advantage is the minimal physical burden on the patient. Through this technology, we aim to provide a safe and accessible treatment option — and ultimately save as many lives as possible.